These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 33807011)

  • 21. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
    Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
    Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.
    Gurney M; O'Dwyer M
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR-NK cells for cancer immunotherapy: from bench to bedside.
    Zhang L; Meng Y; Feng X; Han Z
    Biomark Res; 2022 Mar; 10(1):12. PubMed ID: 35303962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
    Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
    PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology.
    Gunduz M; Ataca Atilla P; Atilla E
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.
    Marofi F; Al-Awad AS; Sulaiman Rahman H; Markov A; Abdelbasset WK; Ivanovna Enina Y; Mahmoodi M; Hassanzadeh A; Yazdanifar M; Stanley Chartrand M; Jarahian M
    Front Oncol; 2021; 11():673276. PubMed ID: 34178661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NK Cell-Based Immunotherapies in Cancer.
    Shin MH; Kim J; Lim SA; Kim J; Kim SJ; Lee KM
    Immune Netw; 2020 Apr; 20(2):e14. PubMed ID: 32395366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy.
    Fabian KP; Hodge JW
    Mol Ther Oncolytics; 2021 Dec; 23():266-276. PubMed ID: 34761106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
    Wang W; Jiang J; Wu C
    Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways.
    Yang Y; Badeti S; Tseng HC; Ma MT; Liu T; Jiang JG; Liu C; Liu D
    Mol Ther Methods Clin Dev; 2020 Sep; 18():428-445. PubMed ID: 32695845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generating natural killer cells for adoptive transfer: expanding horizons.
    Kundu S; Gurney M; O'Dwyer M
    Cytotherapy; 2021 Jul; 23(7):559-566. PubMed ID: 33431318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive cell transfer therapy for malignant gliomas.
    Ishikawa E; Takano S; Ohno T; Tsuboi K
    Adv Exp Med Biol; 2012; 746():109-20. PubMed ID: 22639163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.